PSMA-I&T | CAS#2192281-54-0 | Radioligand

MedKoo Cat#: 556351 | Name: PSMA-I&T

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PSMA-I&T is a PSMA-based radioligand. [177Lu]Lu-PSMA I&T can be used for potential treatment of metastatic castration-resistant prostate cancer. 67 Ga-PSMA I&T can be used for radioguided surgery of lymph node metastases with biochemical recurrence of prostate cancer.

Chemical Structure

PSMA-I&T

CAS#2192281-54-0

Theoretical Analysis

MedKoo Cat#: 556351

Name: PSMA-I&T

CAS#: 2192281-54-0

Chemical Formula: C63H92IN11O23

Exact Mass: 1497.5412

Molecular Weight: 1498.39

Elemental Analysis: C, 50.50; H, 6.19; I, 8.47; N, 10.28; O, 24.56

Price and Availability

Size	Price	Availability
1mg	USD 950.00	Ready to ship
5mg	USD 1,950.00	Ready to ship
10mg	USD 3,650.00	Ready to ship
25mg	USD 5,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

PSMA-I&T; PSMAI&T; PSMA I&T; PSMA-I-T; PSMA-IT;

IUPAC/Chemical Name

(3S,7S,26R,29R,32R)-29-benzyl-32-(4-hydroxy-3-iodobenzyl)-5,13,20,28,31,34-hexaoxo-37-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4,6,12,21,27,30,33-heptaazaheptatriacontane-1,3,7,26,37-pentacarboxylic acid

InChi Key

HPLNQICCRXHOIA-IEHTVPKNSA-N

InChi Code

InChI=1S/C63H92IN11O23/c64-42-34-41(18-21-49(42)76)36-46(67-52(79)22-20-48(62(96)97)75-32-30-73(38-55(84)85)28-26-72(37-54(82)83)27-29-74(31-33-75)39-56(86)87)57(88)69-47(35-40-12-4-3-5-13-40)58(89)68-43(59(90)91)14-8-10-24-65-50(77)16-6-1-2-7-17-51(78)66-25-11-9-15-44(60(92)93)70-63(98)71-45(61(94)95)19-23-53(80)81/h3-5,12-13,18,21,34,43-48,76H,1-2,6-11,14-17,19-20,22-33,35-39H2,(H,65,77)(H,66,78)(H,67,79)(H,68,89)(H,69,88)(H,80,81)(H,82,83)(H,84,85)(H,86,87)(H,90,91)(H,92,93)(H,94,95)(H,96,97)(H2,70,71,98)/t43-,44+,45+,46-,47-,48?/m1/s1

SMILES Code

IC(C=C1C[C@H](C(N[C@@H](C(N[C@@H](C(O)=O)CCCCNC(CCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=O)CC2=CC=CC=C2)=O)NC(CCC(N3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)C(O)=O)=O)=C(C=C1)O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T24D01P30

QC Data

View QC data: current batch, Lot#T24D01P30

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

PSMA I&T is a potent PSMA (prostate-specific membrane antigen) inhibitor.

In vitro activity:

To be determined

In vivo activity:

PSMA I&T has potential as a theranostic tool for prostate cancer (PCa), with blocking agents like 2-PMPA mitigating kidney uptake concerns. PSMA I&T effectively localized in PSMA-expressing tumors but also accumulated in kidneys and salivary glands. However, coadministration of 2-PMPA reduced renal uptake, improving tumor visualization and reducing kidney toxicity during radionuclide therapy. Reference: Theranostics. 2016 Apr 12;6(6):849-61. https://pubmed.ncbi.nlm.nih.gov/27162555/

Preparing Stock Solutions

The following data is based on the product molecular weight 1,498.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Privé BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, Bartholomä M, Maus S, Gotthardt M, Laverman P, Konijnenberg MW, Ezziddin S, Nagarajah J, Heskamp S. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2022 May;49(6):2064-2076. doi: 10.1007/s00259-021-05661-0. Epub 2021 Dec 21. PMID: 34932154. 2. Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. PMID: 27162555; PMCID: PMC4860893.

In vitro protocol:

To be determined

In vivo protocol:

Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. PMID: 27162555; PMCID: PMC4860893.